TIPS联合栓塞粗大自发性门体分流道对术后肝性脑病的影响

摘要/Abstract

摘要： 经颈静脉肝内门体分流术(TIPS)是治疗肝硬化门静脉高压引起的各种并发症的重要方法之一,其术后肝性脑病的发生一定程度上限制了TIPS的广泛应用,预防TIPS术后肝性脑病的发生是临床重点关注的问题之一;另一方面肝硬化门静脉高压患者伴发粗大的自发性门体分流道(SPSS)易发生肝性脑病,既往文献指出,栓塞粗大SPSS是治疗此类患者肝性脑病的有效方法之一。那么TIPS术联合栓塞粗大SPSS能否降低术后肝性脑病的风险？本文针对相关问题进行阐述。

周粟, 袁敏. TIPS联合栓塞粗大自发性门体分流道对术后肝性脑病的影响[J]. 肝脏, 2022, 27(10): 1067-1068.

参考文献

[1] Boike JR, Thornburg BG, Asrani SK, et al. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clin Gastroenterol Hepatol, 2022,20(8):1636-1662.
[2] Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut, 2020,69(7):1173-1192.
[3] Borentain P, Soussan J, Resseguier N, et al. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement. Diagn Interv Imaging, 2016,97(6):643-650.
[4] An J, Kim KW, Han S, et al. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther, 2014,39(12):1418-1426.
[5] Nardelli S, Riggio O, Gioia S, et al. Risk factors for hepatic encephalopathy and mortality in cirrhosis: The role of cognitive impairment, muscle alterations and shunts. Dig Liver Dis, 2022,54(8):1060-1065.
[6] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 2014,60(2):715-735.
[7] Wijdicks EF. Hepatic Encephalopathy. N Engl J Med, 2016,375(17):1660-1670.
[8] Vidal-González J, Quiroga S, Simón-Talero M, et al. Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem.Therap Adv Gastroenterol, 2020, 13:1756284820961287.
[9] Gupta D, Chawla YK, Dhiman RK, et al. Clinical significance of patent paraumbilical vein in patients with liver cirrhosis. Dig Dis Sci, 2000,45(9):1861-1864.
[10] Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol, 2009,50(3):604-620.
[11] Tripathi D, Bureau C. Prophylactic embolization of large spontaneous portosystemic shunts with transjugular intrahepatic portosystemic shunt (TIPS): A panacea for post‐TIPS hepatic encephalopathy?. Hepatology, 2022,76(3):551-553.
[12] Simón-Talero M, Roccarina D, Martínez J, et al. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018,154(6):1694-1705.
[13] Kumamoto M, Toyonaga A, Inoue H, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: Hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol, 2010,25(6):1129-1135.
[14] Saad W. Portosystemic Shunt Syndrome and Endovascular Management of Hepatic Encephalopathy. Semin Intervent Radiol, 2014,31(03):262-265.
[15] Wu Q, Shen L, Chu J, et al. Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis. Oncol Lett, 2015,9(1):347-350.
[16] Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology, 2013,57(6):2448-2457.
[17] He C, Lv Y, Wang Z, et al. Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis. Dig Liver Dis, 2018,50(12):1315-1323.
[18] Leng X, Zhang F, Zhang M, et al. Comparison of transjugular intrahepatic portosystemic shunt for treatment of variceal bleeding in patients with cirrhosis with or without spontaneous portosystemic shunt. Eur J Gastroenterol Hepatol, 2019,31(7):853-858.
[19] Lv Y, Chen H, Luo B, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. Hepatology, 2022,76(3):676-688.
[20] Bureau C, Thabut D, Jezequel C, et al. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial. Ann Intern Med, 2021,174(5):633-640.